- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00288704
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective:
The primary objective of this study was to assess the effect of rilonacept on the clinical signs and symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) when used for chronic therapy as evaluated by the subjects themselves over time using a validated patient-reported outcomes tool.
Secondary Objective(s):
The secondary objectives were as follows:
- To determine the safety and tolerability of rilonacept in subjects with CAPS
- To assess the effect of rilonacept on laboratory measures of inflammation such as acute phase reactants
This was a multi-center, two-part, double-blind, placebo-controlled study (Parts A and B) designed to assess the efficacy, safety, and tolerability of weekly subcutaneous (SC) doses of 160 mg of rilonacept in adult subjects with active CAPS. These phases were followed by extended open-label phases. After written informed consent was obtained, subjects who met the protocol eligibility criteria were enrolled at one of 27 study sites in the United States. The study consisted of a 3-week screening period preceding Part A, a 6-week long double-blind, randomized phase of the study. All subjects were then treated with single-blind rilonacept for 9-weeks, followed by a subsequent 9-week, double-blind, withdrawal phase during which subjects were re-randomized to either rilonacept or placebo. Subjects then continued treatment in a 24-week open-label extension phase (OLE) and a further 112-week long-term open-label extension (LTOLE), during which all subjects received rilonacept and a 6-week post-treatment follow-up period. Amendments 4 and 6 allowed eligible adult and pediatric subjects aged 7 and above to enroll directly into the open-label phases of the trial.
For reporting purposes, the 24-week OLE and the 112-week LTOLE was considered one Open Label Extension (OLE) phase. This occurred after the 24-week double blind (Parts A and B ) phase. In other words, OLE Week 1 corresponded to the week 25 in the study.
OLE Week 72 was the final timepoint where efficacy was measured. Safety continued after that timepoint until the end of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72204
-
-
California
-
Palm Desert, California, United States, 92260
-
Upland, California, United States, 91786
-
-
Florida
-
Jacksonville, Florida, United States, 32216
-
Stuart, Florida, United States, 34996
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
-
Columbus, Georgia, United States, 31904
-
-
Illinois
-
Aurora, Illinois, United States, 60504
-
-
Kentucky
-
Louisville, Kentucky, United States, 40215
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71105
-
-
Michigan
-
Chesterfield, Michigan, United States, 48047
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
-
-
New York
-
New York, New York, United States, 10023
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27609
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
-
-
South Carolina
-
Columbia, South Carolina, United States, 29201
-
Greer, South Carolina, United States, 29651
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37403
-
-
Texas
-
Dallas, Texas, United States, 75235
-
Waco, Texas, United States, 76712
-
-
Utah
-
Cedar City, Utah, United States, 84720
-
-
Virginia
-
Forest, Virginia, United States, 24551
-
-
Washington
-
Lakewood, Washington, United States, 98499
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Double-blind phases: adults age 18 and above; Open-label extension: Adults and children aged 7 years and older.
- Was diagnosed with Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS) based upon clinical signs and symptoms
- Had documented mutation in NLRP-3 (Cold Induced Autoinflammatory Syndrome-1 or CIAS1) in subject or relative, and willingness to have a confirmatory genetic (Deoxyribonucleic acid or DNA) test (cheek swab).
- Was able to understand and comply with study procedures and was able to provide informed consent
- If female, was not currently pregnant and was willing to use contraception during the study
Exclusion Criteria:
- Had evidence of untreated tuberculosis or other conditions/therapies that made the subject inappropriate for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Some subjects were treated with Placebo in the Study.
This occurred (if subject randomized to Placebo) either during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24).
|
Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24).
On Day 1, subjects received two placebo injections.
|
Active Comparator: rilonacept 160 mg
If randomized to rilonacept, subjects received this treatment during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24). All subjects received rilonacept 160 mg during weeks 6-14 (between Parts A and B). Study drug is administered as a 2.0 mL subcutaneous injection once a week. At baseline (week 0) subjects receive a loading dose of rilonacept 320 mg. |
Rilonacept was given by subcutaneous injection.
It was administered weekly at the dose of 160mg.
On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
Other Names:
Rilonacept was given by subcutaneous injection.
It was administered weekly at the dose of 160mg.
No loading dose was given for subjects who entered directly into the open-label.
|
Other: Open-Label rilonacept 160 mg
After week 24 (the end of part B), all subjects went into weekly dosing of open label rilonacept 160 mg. During this phase of the study, adolescents aged 7 and above were entered into the study and rilonacept was dosed as 2.2 mg/kg injections, up to 160 mg, per week. Study drug is administered as a 2.0 mL subcutaneous injection once a week. |
Rilonacept was given by subcutaneous injection.
It was administered weekly at the dose of 160mg.
On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
Other Names:
Rilonacept was given by subcutaneous injection.
It was administered weekly at the dose of 160mg.
No loading dose was given for subjects who entered directly into the open-label.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS)
Time Frame: Baseline (Days -21 to -1) and Week 6 (Days 21-42)
|
The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue). KSS was averaged over two 21-day daily reporting periods (the 3 weeks prior to both baseline and week 6). In part A, a negative change in mean values indicated improvement under treatment with rilonacept in symptoms. The DHAF was used because it is a validated instrument to collect subject's self-reported responses. |
Baseline (Days -21 to -1) and Week 6 (Days 21-42)
|
Mean Change in Key Symptom Score (KSS) From Week 15 to Week 24 (During the Randomized Withdrawal Phase or Part B)
Time Frame: Week 15 through Week 24 (randomized withdrawal)
|
The mean Key Symptom Score (KSS --from the validated, patient-administered DHAF) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue). Subjects all received rilonacept 160 mg from week 6 through week 14. At week 15, subjects were re-randomized in a 1:1 ratio between Placebo and rilonacept 160 mg. Subjects baseline period was the 21-day period prior to week 15 randomization. A positive score indicated a worsening of symptoms versus an active treatment rilonacept baseline period. |
Week 15 through Week 24 (randomized withdrawal)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline to Endpoint (Week 6) in Number of Disease Flare Days Per Patient
Time Frame: Baseline to Week 6 (Part A)
|
A Disease flare day was any day where the mean Key Symptom Score (KSS) was greater than 3. The KSS was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue). KSS was calculated for 21 Day Periods at baseline and at the endpoint (from Weeks 3 - 6). The difference in the number of flares between the two periods was averaged for all subjects. The DHAF was used because it is a validated instrument to collect subject's self-reported responses. It was the basis for the KSS and the flare day count. |
Baseline to Week 6 (Part A)
|
Change From Baseline to Endpoint (Week 6) in Physician's Global Assessment
Time Frame: Baseline to Week 6 (Part A)
|
The Physician's Global Assessment was an evaluation at each visit on a scale of 0=no disease activity to 10=severe disease activity.
A negative value in change in Physician's Global Assessment is indicative of an improvement.
|
Baseline to Week 6 (Part A)
|
Mean Change From Baseline to Endpoint (Week 6) in Patient's Global Assessment
Time Frame: Baseline to Week 6 (Part A)
|
The Patient's Global Assessment was a question on the Daily Health Assessment Form "Considering all the ways that Familial Cold Autoinflmatory Syndrome (FCAS) /Muckle-Wells Syndrome (MWS) affects you, please rate how you are doing based on the following scale" 0=very well to 10=very poor.
A negative value in change in Patient's Global Assessment is indicative of an improvement.
|
Baseline to Week 6 (Part A)
|
Median Change From Baseline to Week 6 (Part A) Endpoint in C-Reactive Protein (mg/L)
Time Frame: Baseline to Endpoint of Part A
|
An abnormal value for CRP was considered > 8.4 mg/L.
|
Baseline to Endpoint of Part A
|
Median Change From Baseline to Week 6 (Part A) Endpoint in Serum Amyloid A (mg/L)
Time Frame: Baseline to Endpoint of Part A
|
An abnormal value for SAA was considered > 6.4 mg/L.
|
Baseline to Endpoint of Part A
|
Number of Subjects With at Least 30% Improvement in Key Symptoms Scores (KSS) From Baseline to Endpoint (Week 6)
Time Frame: Baseline to Endpoint (Week 6)
|
The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue).
|
Baseline to Endpoint (Week 6)
|
Number of Subjects With at Least 50% Improvement in Key Symptoms Scores (KSS) From Baseline to Endpoint (Week 6)
Time Frame: Baseline to Week 6 (Part A)
|
The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue).
|
Baseline to Week 6 (Part A)
|
Number of Subjects With at Least 75% Improvement in Key Symptoms Scores (KSS) From Baseline to Endpoint (Week 6)
Time Frame: Baseline to Week 6 (Part A)
|
The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue).
|
Baseline to Week 6 (Part A)
|
Summary of Mean Change From Baseline to Open-Label Extension Week 72 in KSS
Time Frame: From Baseline (week 0) to OLE Week 72
|
OLE Week 72 was the last timepoint at which efficacy was measured in the study. 56 of the 101 OLE subjects were included in the analysis. The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue). A negative change in mean values indicated improvement in symptoms. |
From Baseline (week 0) to OLE Week 72
|
Change From Baseline to Open-Label Extension Week 72 in Patient's Global Assessment
Time Frame: From Baseline (Week 0) to OLE Week 72
|
The Patient's Global Assessment was a question on the Daily Health Assessment Form "Considering all the ways that FCAS/MWS affects you, please rate how you are doing based on the following scale" 0=very well to 10=very poor. A negative value in change in Patient's Global Assessment is indicative of an improvement. OLE Week 72 was the last timepoint at which efficacy was measured in the study. 56 of the 101 OLE subjects were included in the analysis. |
From Baseline (Week 0) to OLE Week 72
|
Change From Baseline to Open-Label Extension Week 72 in Number of Disease Flare Days
Time Frame: From Baseline (Week 0) to OLE Week 72
|
OLE Week 72 was the last timepoint at which efficacy was measured in the study. 56 of the 101 OLE subjects were included in the analysis. A Disease flare day was any day where the mean Key Symptom Score (KSS) was greater than 3. The mean Key Symptom Score (KSS --from the validated, patient-administered Daily Health Assessment Form(DHAF)) was the average on a 0-10 scale (0=None, 10=Very Severe) of 5 separate scales -- rash, feeling of fever/chills, joint pain, eye redness/pain, and fatigue). |
From Baseline (Week 0) to OLE Week 72
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Robert Evans, PharmD., Regeneron Pharmaceuticals
Publications and helpful links
General Publications
- Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012 Oct;34(10):2091-103. doi: 10.1016/j.clinthera.2012.09.009. Epub 2012 Sep 29.
- Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008 Aug;58(8):2443-52. doi: 10.1002/art.23687.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Disease
- Hereditary Autoinflammatory Diseases
- Skin Diseases, Genetic
- Skin Diseases, Vascular
- Hypersensitivity
- Syndrome
- Genetic Diseases, Inborn
- Urticaria
- Cryopyrin-Associated Periodic Syndromes
- Anti-Inflammatory Agents
- Rilonacept
Other Study ID Numbers
- IL1T-AI-0505
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genetic Diseases, Inborn
-
Duke UniversitySuspendedLysosomal Storage Diseases | Genetic Disease | Inborn Errors of Metabolism | Glycogen Storage Disease | Storage DiseaseUnited States
-
Vanderbilt University Medical CenterRecruitingGenetic DiseaseUnited States
-
Rady Pediatric Genomics & Systems Medicine InstituteActive, not recruiting
-
Illumina, Inc.Medical College of WisconsinActive, not recruitingGenetic DiseaseUnited States
-
Igentify LtdSheba Medical CenterUnknown
-
Rady Pediatric Genomics & Systems Medicine InstituteRecruiting
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Kevin BruceNot yet recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States